To address this fear, clinicians should be knowledgeable about the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) study, which showed that insulin glargine 100 U/mL has a neutral effect on cardiovascular outcomes overall and a beneficial effect on microvascular complications, and the DEVOTE study, which established insulin degludec 100 U/mL as having a similar effect to insulin glargine 100 U/mL on the risk of cardiovascular events
This mirrors most state Medicaid programs and most private insurers, which have been slow to cover investigational anti-obesity medications
But the entire curve sits lower on the graph
After you sign up, heres how the process works from start to finish: Quick Pre-Qualification Quiz Answer a few questions to see if GLP-1 treatment may be right for you
Minimal Lifestyle Disruption : Unlike restrictive diets or invasive surgery, GLP-1 therapy allows for gradual, sustainable weight loss without the need for drastic lifestyle changes